Chaihu-Shugan-San for patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis DOI Creative Commons

Xiang-Ke Qu,

Jianrong Sun,

Yue Shen

et al.

Medicine, Journal Year: 2025, Volume and Issue: 104(18), P. e42303 - e42303

Published: May 2, 2025

Background: Nonalcoholic fatty liver disease (NAFLD) is a chronic characterized by intrahepatic accumulation and closely associated with metabolic problems. Some studies have indicated that Chaihu-Shugan-San (CSS) may positive effect on NAFLD, but robust evidence-based research to substantiate the application of CSS scarce. A meta-analysis was conducted assess clinical efficacy safety in treatment for NAFLD. Methods: The literature reporting NAFLD searched from inception October 2023 7 Chinese or English databases. Studies were screened incorporated based predefined criteria. Data extracted quality assessed independently 2 researchers according Cochrane risk bias tools. changes outcomes analyzed using mean difference (MD) 95% confidence intervals (CIs) random- fixed-effects model examine CSS. RevMan5.4 software used perform meta-analyses, meta package R 4.0.0 publication analysis. Results: total 17 involving 1576 participants meta-analysis. There high heterogeneity among all continuous outcomes. Compared common treatments, could decrease aspartate-aminotransferase (MD = −12.02, CI [−15.97, −8.07]), alanine-aminotransferase −10.89, [−16.35, −5.43]), triglyceride cholesterol levels. In addition, increase high-density lipoprotein And, lower incidence adverse events (RR 0.79, [0.33, 1.91]). Conclusion: Current evidence shows single combined use effective enzymes blood lipids. Nevertheless, it challenging reach conclusive determination owing significant ambiguous some trials. Therefore, more high-quality required implementation

Language: Английский

Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs DOI Creative Commons

Xing Wan,

Jingyuan Ma,

He Bai

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(1), P. 140 - 140

Published: Jan. 17, 2025

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic and is closely associated with metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), syndrome. However, effective treatment strategies for NAFLD are still lacking. In recent years, progress been made in understanding pathogenesis of NAFLD, identifying multiple therapeutic targets providing new directions drug development. This review summarizes advances focusing on mechanisms action natural products, small-synthetic-molecule drugs, combination therapy strategies. aims to provide insights treating NAFLD.

Language: Английский

Citations

2
The Protective Potential of Blighia sapida on the Behavioural and Hematobiochemical Disruption in Kerosene-exposed Clarias gariepinus: In Vivo and In Silico Evaluation DOI
Mukaila B. Adekola,

O. C. Ojelade,

S. A. Olurode

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown, P. 100036 - 100036

Published: March 1, 2025

Language: Английский

Citations

0
Chaihu-Shugan-San for patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis DOI Creative Commons

Xiang-Ke Qu,

Jianrong Sun,

Yue Shen

et al.

Medicine, Journal Year: 2025, Volume and Issue: 104(18), P. e42303 - e42303

Published: May 2, 2025

Background: Nonalcoholic fatty liver disease (NAFLD) is a chronic characterized by intrahepatic accumulation and closely associated with metabolic problems. Some studies have indicated that Chaihu-Shugan-San (CSS) may positive effect on NAFLD, but robust evidence-based research to substantiate the application of CSS scarce. A meta-analysis was conducted assess clinical efficacy safety in treatment for NAFLD. Methods: The literature reporting NAFLD searched from inception October 2023 7 Chinese or English databases. Studies were screened incorporated based predefined criteria. Data extracted quality assessed independently 2 researchers according Cochrane risk bias tools. changes outcomes analyzed using mean difference (MD) 95% confidence intervals (CIs) random- fixed-effects model examine CSS. RevMan5.4 software used perform meta-analyses, meta package R 4.0.0 publication analysis. Results: total 17 involving 1576 participants meta-analysis. There high heterogeneity among all continuous outcomes. Compared common treatments, could decrease aspartate-aminotransferase (MD = −12.02, CI [−15.97, −8.07]), alanine-aminotransferase −10.89, [−16.35, −5.43]), triglyceride cholesterol levels. In addition, increase high-density lipoprotein And, lower incidence adverse events (RR 0.79, [0.33, 1.91]). Conclusion: Current evidence shows single combined use effective enzymes blood lipids. Nevertheless, it challenging reach conclusive determination owing significant ambiguous some trials. Therefore, more high-quality required implementation

Language: Английский

Citations

0